Arthneeti
All Q3 FY25 results →
PI

P I Industries Ltd

Q3 FY25Fertilizers & Agrochemicals

P I Industries Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹2,497
Market cap₹42.6K Cr
P/E35.5
Updated23 Aug 2026
Read5 min read

The short version

PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY. - Domestic branded revenue is growing at about 5% with volume growth at 8%. - The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase. - Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally. - New verticals like pharma, biologics, and electronic chemicals are expected to meaningfully contribute in 2-3 years. - Agrochemical markets are mixed currently, but visibility is expected to improve in the next 1-2 quarters. - CAPEX plans include building new multiproduct plants to support future growth with Rs. Pharma CDMO and biologicals are new growth verticals targeting multi-billion-dollar markets with potential 20-25% CAGR over the next 2-3 years. - Pharma business expected to breakeven and achieve critical mass (Rs.

From P I Industries Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY.
  • Domestic branded revenue is growing at about 5% with volume growth at 8%.
  • The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase.
  • Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally.
  • New verticals like pharma, biologics, and electronic chemicals are expected to meaningfully contribute in 2-3 years.

2 more points from P I Industries Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what P I Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • PI Industries plans to invest in building two new multiproduct plants in the coming year to meet future business requirements.
  • The capital expenditure (CAPEX) guidance for the next year is estimated between Rs. 800 to 1,000 crore.
  • Pharma segment CAPEX includes investments in hardware, software, and regulatory compliance to build capabilities across the value chain; this investment phase will take a couple of years to generate significant value.

2 more points from P I Industries Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Anya Polytech &
Rev 2Mar 1
2Dharmaj Crop
Rev 2Mar 2
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what P I Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The order book remains approximately at the same level, around USD 1.4 billion (Page 10).
  • Growth is influenced not only by the order book but also by annual purchase orders and long-term agreements (Page 9).
  • The company is maintaining and sustaining current volumes, with overall industry conditions being in transition due to trade wars, tariffs, and other challenges (Page 9).
  • Clarity on growth visibility for FY26 or FY27 is expected in the next one or two quarters (Page 9).

P I Industries Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.6K Cr, net profit ₹200 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What P I Industries Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

  • Sumitomo Chemi. (Q3 FY25)

    641.9 crore, up 18% YoY from Rs. Key concall takeaways from Sumitomo Chemical India Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

  • Dharmaj Crop (Q3 FY25)

    Q3FY25 Revenue from Operations: ₹1,745 million . Key concall takeaways from Dharmaj Crop Guard Ltd's Q3 FY25 earnings call — and how it ranks against sector…

  • Punjab Chemicals & Crop Protection Ltd (Q3 FY25)

    Capacity utilization for agrochemical division is at 72%, performance chemicals at 52%, with expansion plans underway, supporting growth (Page 3). Key concall…

  • M B Agro Prod. (Q3 FY25)

    However, it highlights strong demand for NPK fertilizers with a 50% YoY industry demand growth in the quarter. Key concall takeaways from M B Agro Prod.'s Q3…

Compare:vs Coromandel Intervs F A C Tvs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

P I Industries Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were P I Industries Ltd Q3 FY25 results?

PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY. - Domestic branded revenue is growing at about 5% with volume growth at 8%. - The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase. - Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally. - New verticals like pharma, biologics, and electronic chemicals are expected to meaningfully contribute in 2-3 years. - Agrochemical markets are mixed currently, but visibility is expected to improve in the next 1-2 quarters. - CAPEX plans include building new multiproduct plants to support future growth with Rs. Pharma CDMO and biologicals are new growth verticals targeting multi-billion-dollar markets with potential 20-25% CAGR over the next 2-3 years. - Pharma business expected to breakeven and achieve critical mass (Rs.

What is P I Industries Ltd share price analysis?

P I Industries Ltd currently shows a neutral. The stock trades at a P/E of 35.5 with a market cap of ₹42,633 Cr. Investors should review the full earnings analysis for detailed insights.

Is P I Industries Ltd planning capital expenditure?

PI Industries plans to invest in building two new multiproduct plants in the coming year to meet future business requirements. - The capital expenditure (CAPEX) guidance for the next year is estimated between Rs.

Keep P I Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.